AzTrials
AzTrials

Postoperative PainPhase 1NCT05141344

Effect of Oral Melatonin on Postoperative Analgesia After Thoracotomy in Infants

A Phase 1 study testing Melatonin 3 MG Oral Tablet in people with Postoperative Pain, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Thoracotomy pain is one of the severest pain that should be taken seriously, especially in children. (1) Inadequate postoperative pain management can compromise respiratory function, delay postoperative extubation, increase the cost and delay hospital discharge. Read more about this study

Who is it for?
Ages 1 month to 18 months
Conditions the study is for
Postoperative Pain
What is being tested?
Melatonin 3 MG Oral Tablet
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteEgypt
Study dates
15 Dec 2021to 10 Jun 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 18 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • American Society of Anesthesiology( ASA) I, II
  • less than 18months.
  • males and females.
  • scheduled for thoracotomy for closed cardiac surgery.

Who cannot join

  • airway abnormalities.
  • heart failure.
  • endocrine disorders.
  • Patients with hypersensitivity to any drug.
  • beta blockers, any analgesics recieved within 24 h before surgery, or any psychotropic drugs.
  • hepatic, renal diseases neuromuscular disease,
Show all 9Show fewer
  • coagulopathy.
  • a history of hyperthermia.
  • infection at the site of the block.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Amany Hassan Saleh

    Giza, 02

Other trials in Egypt

About this study

Official title: The Effect of Pre-emptive Oral Melatonin Versus Placebo on Postoperative Analgesia in Infants After Thoracotomy for Closed Cardiac Surgeries: A Randomized Controlled Study.

Thoracotomy pain is one of the severest pain that should be taken seriously, especially in children. (1) Inadequate postoperative pain management can compromise respiratory function, delay postoperative extubation, increase the cost and delay hospital discharge.

Opioids are the most commonly used analgesics to manage postoperative pain; however, they have many possible unfavorable side effects, such as nausea, vomiting, pruritus, and respiratory depression. (3) Melatonin is an endogenous indoleamine secreted by the pineal gland. It has several important physiological functions, including regulation of the circadian rhythms, modulation of season changes, antioxidant, anti-inflammatory, and anticonvulsant effects. (4)

Read the detailed description

The analgesic effect of melatonin may be referred to as Gi-coupled melatonin receptors, to Gi-coupled opioid-l-receptors or gamma-aminobutyric acid (GABA) receptors with a consequential reduction in anxiety and pain. (5) Gitto and co-workers(6) hypothesized that melatonin may have beneficial effects as an analgesic effect in preterm newborns that are subject to painful procedures, such as endotracheal intubation and mechanical ventilation without detected side effects. Pro-inflammatory and anti-inflammatory cytokines related to pain were more in the common sedation and analgesia group than in melatonin-treated infants suggesting the use of melatonin as an adjunct analgesic therapy during procedural pain. (6) Therefore Melatonin may be a useful perioperative drug as it does not have any known undesirable serious adverse effects. (7)

To the best of investigators' knowledge, this is the first study investigating the effect of melatonin on postoperative pain scores after thoracotomy in infants.

Being tested
Melatonin 3 MG Oral Tablet, Placebo
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Melatonin 3 MG Oral TabletDrug

    it will be given orally one hour preoperatively

  • PlaceboDrug

    sugar-coated tablets will be given one hour preoperatively

Study groups in NCT05141344
Study groupRoleWhat they receive
melatonin groupActive comparatorpatients in this group will be premedicated One hour before the start of surgery by receiving 0.5mg/kg orally of melatonin (Melatonin 3 mg ), (the tablet will be dissolved in 5 ml of water, to be given by syringe 5ml) in the preoperative unit
Receives: Drug: Melatonin 3 MG Oral Tablet
placebo groupPlacebo comparatorpatients in group P (n =25 ) will receive a placebo( sugary tablets dissolved in 5ml of water by syringe 5 ml) one hour before the start of surgery.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. total pethidine consumption 24 hours postoperatively.

    total dose of pethidine given to the patients over 24 hours postopertively

    Measured: 24 hours

Secondary outcomes (2)
  1. the intraoperative fentanyl consumption

    total fentanyl doses in ug

    Measured: 2 hours

  2. Neonatal-Infant pain scale

    0 no pain 0-3 mild pain 3-5 moderate pain 5-7 severe pain

    Measured: 4 hours,6 hours,8 hours,12 hours,18 hours, 24 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2021
  2. Study start15 Dec 2021
  3. Primary completion22 May 2022
  4. Study completion10 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
50 patients will be divided into 2 equal groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05141344
Sponsor's protocol ID
N-101-2021
Status last verified
Jul 2022
First submitted
19 Nov 2021
Last updated
20 Jul 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Melatonin 3 MG Oral Tablet in people with Postoperative Pain, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

total pethidine consumption 24 hours postoperatively. (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in